Therefore, this study aims to analyze clinicopathological and genomic characteristics of Latin American patients with KRAS-mutated advanced NSCLC, focusing on their impact on therapeutic outcomes. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.